Dr Jonathan Lancaster speaks with ecancer at SABCS 2017 about an updated genomic screening tool for life-time breast cancer risk.

He outlines how the test assesses 86 single nucleotide polymorphisms linked to cancer aetiology to provide clinically validated likelihood of disease.

Dr Lancaster considers the potential psychological impact for women with a family history of breast cancer, and notes that this tool is a modified function of existing myRisk assays, already in clinical use, so can be introduced to practice quickly and at no cost.